Bronchogen
ExperimentalKhavinson bioregulator / researchExperimental
Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.
For research use only.
Key Facts
- CAS
- 167174-49-0
- Molecular Weight (MW)
- 391.39 g/mol
- Half-life
- Not established (small tripeptide)
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Bronchial epithelium (proposed)
Overview
Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.
Protocol
- Dosage Range
- Per research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Tetrapeptide bioregulator claimed to normalize bronchial epithelium gene expression in older Russian cytogenetic papers. Mechanism is not established in Western controlled trials.
Targets
Bronchial epithelium (proposed)
Studies
- Khavinson peptide bioregulators overview— Journal/year not available
Benefits
Respiratory-epithelium research (historical RU literature)
Potential Side Effects
- Not characterized in modern RCTs
References
- PMID 15587334External link · Year —